Huntington's Disease: Treatment
Treatment of Huntington's disease (HD) is symptomatic and multidisciplinary. There is currently no disease-modifying therapy, though several candidates are in advanced clinical trials (see Disease-Modifying Trials). The pharmacologic management of HD focuses on three domains: chorea (the most visible motor symptom), neuropsychiatric symptoms (often more disabling than the movement disorder), and other motor phenomena that emerge as the disease progresses. Three FDA-approved VMAT2 inhibitors now form the backbone of chorea treatment. Rehabilitation and multidisciplinary care are integral to managing this complex, progressive disease. The availability of valbenazine (FDA-approved for HD chorea in 2023) as a once-daily option represents the most recent pharmacologic advance.
Bottom Line
- VMAT2 inhibitors are the standard of care for HD chorea: Tetrabenazine (TID, FDA 2008), deutetrabenazine (BID, FDA 2017), and valbenazine (QD, FDA 2023) — all have Class I evidence. All carry boxed warnings for depression and suicidality
- Valbenazine offers once-daily dosing and may have a lower depression/suicidality risk than the other VMAT2 inhibitors; contraindicated in severe renal impairment
- Dopamine receptor-blocking drugs (DRBDs) are widely used, especially when psychiatric comorbidities (psychosis, aggression) co-exist; higher D2 affinity = greater chorea suppression but more risk of tardive syndromes
- Late-stage HD shifts from chorea-predominant to parkinsonism and dystonia — VMAT2 inhibitors may need to be reduced or discontinued; close pharmacotherapy monitoring essential
- Suicidal ideation (30%) and psychiatric symptoms should be addressed at every visit; SSRIs first-line for depression and anxiety; monitor for SSRI-induced apathy
- Multidisciplinary care: PT (balance, falls, mobility), OT (ADLs), SLP (communication, dysphagia), dietitian (high-calorie needs), genetics counselor, psychology/psychiatry, social work
Pharmacologic Management of Chorea
VMAT2 Inhibitors: Mechanism
Vesicular monoamine transporter 2 (VMAT2) inhibitors work by blocking the packaging of dopamine into presynaptic vesicles, thereby depleting presynaptic dopamine stores. This reduces dopaminergic activation of the nigrostriatal pathway and suppresses chorea. All three agents are contraindicated with monoamine oxidase inhibitors (MAOIs).
| Agent | Half-Life | Dosing | Frequency | Key Trial(s) | Side Effects | Contraindications |
|---|---|---|---|---|---|---|
| Tetrabenazine | 5–7 hours | Start 12.5 mg; max 50 mg/day (HD), 75 mg/day (TD) | TID | TETRA-HD (Class I: improved UHDRS chorea scores) | Sedation, fatigue, insomnia, nausea, anxiety, depression; boxed warning: depression and suicidality | Hepatic impairment, uncontrolled depression or suicidal ideation, MAOIs |
| Deutetrabenazine | 9–10 hours (also extended-release) | Start 12 mg; max 48 mg/day | BID | First-HD (HD chorea), ARM-TD, AIM-TD (TD) | Sedation, headache, anxiety, depression, dry mouth, akathisia, QTc prolongation (rare); boxed warning: depression and suicidality | Hepatic impairment, uncontrolled depression or suicidal ideation, MAOIs |
| Valbenazine | 15–22 hours | Start 40 mg; max 80 mg/day | QD | KINECT-3 (TD), KINECT-HD (HD chorea) | Sedation, headache, akathisia, dry mouth; boxed warning: depression and suicidality (may be less frequent than other VMAT2 inhibitors) | Severe renal impairment, MAOIs |
Choosing a VMAT2 Inhibitor
- Tetrabenazine: First FDA-approved (2008); TID dosing limits adherence; CYP2D6 metabolism — poor metabolizers may need lower doses (consider CYP2D6 genotyping). More frequent depression/suicidality concerns
- Deutetrabenazine: Deuterated form with longer half-life, stabilized plasma levels, and improved sedation profile; BID dosing; also approved for TD
- Valbenazine: Prodrug form with significantly prolonged half-life enabling once-daily dosing (adherence advantage); approved for both HD chorea (2023) and TD (2017); may have lower depression/suicidality risk; contraindicated in severe renal impairment (unlike the others, which are contraindicated in hepatic impairment)
VMAT2 Inhibitor Safety Considerations
- All three carry FDA boxed warnings for depression and suicidality in HD patients
- Monitor for parkinsonism (dose-dependent dopamine depletion effect)
- Screen for depression and suicidal ideation at each visit before and during treatment
- Do not use concomitantly with MAOIs
- VMAT2 inhibitor cost and limited global availability remain barriers — DRBDs continue to be used widely, especially outside the US
Dopamine Receptor-Blocking Drugs (DRBDs)
DRBDs (neuroleptics/antipsychotics) reduce chorea by blocking the postsynaptic dopamine D2 receptor. Higher D2 receptor affinity correlates with greater chorea suppression:
| Agent | D2 Affinity | Key Considerations |
|---|---|---|
| Olanzapine | Higher | Greater chorea suppression; weight gain (may be beneficial in cachectic HD patients); metabolic syndrome risk |
| Risperidone | Higher | Effective chorea suppression; parkinsonism risk |
| Aripiprazole | Moderate (partial agonist) | Partial D2 agonist; may be better tolerated; less sedation |
| Quetiapine | Lower | Less chorea suppression; more useful for psychiatric symptoms (insomnia, agitation) than for chorea |
Practical considerations: DRBDs are preferred when psychiatric comorbidities (psychosis, severe aggression) co-exist, as they simultaneously address both chorea and behavioral symptoms. However, clinicians must monitor for sedation, parkinsonism, metabolic syndrome, and tardive syndromes — TD can co-occur with HD chorea. The cost and limited global availability of VMAT2 inhibitors, combined with the psychiatric benefit of DRBDs, have resulted in ongoing widespread DRBD use for chorea management worldwide.
Other Medications for Chorea
- Amantadine: Limited evidence for HD or TD; commonly used for levodopa-induced dyskinesia in PD but not a standard HD treatment
- Valproic acid / carbamazepine: Useful in Sydenham chorea and juvenile-onset HD with seizures; not standard for adult-onset HD chorea
- Benzodiazepines: May provide mild chorea suppression; more useful for anxiety and muscle spasm
Management of Neuropsychiatric Symptoms
Neuropsychiatric symptoms are often more disabling than motor features. Management should be patient-centered and collaborative with psychiatry, psychology, and social work. Behavioral strategies should be included alongside pharmacotherapy.
| Symptom | First-Line Approach | Notes |
|---|---|---|
| Depression | SSRIs (citalopram, sertraline, fluoxetine), SNRIs (venlafaxine) | Very common; may present years before motor onset. Monitor for SSRI-induced apathy. Mirtazapine useful when appetite stimulation is also needed |
| Anxiety | SSRIs; buspirone; benzodiazepines (short-term) | Common and worsens motor symptoms; address triggers including disease awareness |
| Irritability / aggression | SSRIs; mood stabilizers (valproate, carbamazepine); atypical antipsychotics (olanzapine, quetiapine) | Often the most disruptive symptom for caregivers; behavioral strategies essential |
| Psychosis | Atypical antipsychotics (olanzapine, risperidone, aripiprazole, quetiapine) | Simultaneously addresses chorea and psychosis; monitor for parkinsonism and metabolic effects |
| Apathy | Reduce/discontinue SSRIs if contributing; consider bupropion, methylphenidate (limited evidence) | Distinct from depression — loss of motivation/initiative without sadness. Antidepressants (especially SSRIs) can worsen apathy |
| Obsessive-compulsive behaviors | SSRIs (higher doses may be needed); behavioral therapy | Overlap with frontal executive dysfunction; perseveration common |
| Insomnia / sleep disruption | Sleep hygiene; melatonin; trazodone; quetiapine (low dose) | Sleep disruption is multifactorial: circadian dysfunction, chorea, depression, medications |
Suicidality in HD
Suicidal ideation is present in up to 30% of HD patients. Suicide is the third most common cause of death (6.6%) after pneumonia and infections. Mental health must be a focus of every clinic visit. If firearms are present in the home, safety should be addressed early in the diagnostic process. Orbitofrontal disinhibition and impulsiveness compound the risk. VMAT2 inhibitors carry boxed warnings for depression and suicidality, and tetrabenazine in particular may worsen depressive symptoms. Screen and document at every visit.
Management of Other Motor Symptoms
| Symptom | Treatment Approach |
|---|---|
| Late-stage parkinsonism | As chorea decreases and parkinsonism worsens in advanced HD, VMAT2 inhibitors may need to be reduced or discontinued. Small doses of levodopa may be considered, though evidence is limited. Close monitoring of pharmacotherapy is essential to match the evolving motor phenotype |
| Dystonia | Botulinum toxin for focal dystonia (e.g., cervical, limb); benzodiazepines; baclofen. DRBDs may worsen dystonia in some patients. Dystonic posturing of hands and feet is common in advanced HD |
| Myoclonus | Clonazepam, valproic acid, levetiracetam. More common in juvenile-onset HD |
| Dysphagia | SLP assessment; modified textures; postural strategies; weight monitoring. Leading cause of aspiration pneumonia (the #1 cause of death in HD) |
| Dysarthria | SLP: communication strategies, augmentative/alternative communication devices as disease progresses |
| Gait instability / falls | PT: strength and balance training, assistive devices (walker, wheelchair). Wide-based, lurching gait has choreiform and dystonic components |
| Bruxism | Dental guards; botulinum toxin to masseters in severe cases |
Deep Brain Stimulation
DBS is an investigational, palliative approach for HD chorea:
- Tends to improve resting chorea more than action-induced chorea
- Important to establish that the patient is aware of and disabled by the chorea (anosognosia is common)
- Less effective in HD with predominantly dystonic presentations compared with choreic presentations
- The complexity of HD makes both target selection and overall utility challenging; multidisciplinary team approach recommended
- Also studied (investigationally) for chorea-acanthocytosis, neuroacanthocytosis, and other hyperkinetic disorders
Rehabilitation and Multidisciplinary Care
Rehabilitation and multidisciplinary care are integral to disease management in HD and should be initiated early and adapted as the disease progresses.
| Discipline | Role in HD |
|---|---|
| Physical therapy | Balance, falls prevention, mobility, strength training, assistive devices; gait training addresses wide-based lurching gait with choreiform components |
| Occupational therapy | Daily task adaptation (both physically and cognitively driven impairments); home safety; assistive devices for ADLs |
| Speech-language pathology | Communication strategies (progressive dysarthria); swallowing assessment and management (dysphagia is a leading cause of aspiration pneumonia) |
| Dietitian | High-calorie dietary planning to meet the increased metabolic demands of choreic disorders; prevent wasting; manage dysphagia-related dietary modifications |
| Genetic counselor | Pre- and post-test counseling; family planning (IVF with preimplantation genetic testing); cascade testing in family members; navigate insurance and ethical implications |
| Psychology / psychiatry | Depression, anxiety, suicidality screening and management; behavioral strategies for aggression and OCD; cognitive rehabilitation; caregiver support |
| Social work | Community resources, support groups, disability planning, firearm safety, driving assessment, stigma reduction, care coordination |
| Palliative care | Holistic approach focusing on patient goals and symptom palliation; advance care planning; hospice transition in late-stage disease |
Caregiver Support
Caregiver burden in HD is uniquely challenging. At-risk family caregivers may themselves face the possibility of developing HD, adding emotional weight to the physical toll. Care partners should be included in treatment discussions (especially given patient anosognosia) and offered their own psychological support, respite care, and connection to HD support organizations such as the Huntington's Disease Society of America (HDSA). Community education and awareness efforts help reduce stigma.
Treatment of Secondary Chorea
Initial treatment for any secondary (non-HD) chorea should be directed at the underlying cause:
- Tardive dyskinesia: Remove offending DRBA if clinically possible; consider switch to lower D2-affinity agent (e.g., clozapine); VMAT2 inhibitors (deutetrabenazine, valbenazine both FDA-approved for TD); vitamin B6 has some evidence (monitor for neuropathy)
- Sydenham chorea: Penicillin; 2024 meta-analysis supports antibiotics + corticosteroids + valproic acid for symptom resolution and recurrence prevention; carbamazepine for symptomatic benefit
- Nonketotic hyperglycemia: Blood glucose correction; symptomatic chorea management may be needed for weeks–months
- Autoimmune: Immunotherapy (plasma exchange, IVIg, rituximab) for autoimmune and paraneoplastic chorea
- Drug-induced: Remove offending agent when possible
Key References
- Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial (TETRA-HD). Neurology. 2006;66(3):366–372.
- Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease (First-HD). JAMA. 2016;316(1):40–50.
- Furr Stimming E, Claassen DO, Kayson E, et al. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD). Lancet Neurol. 2023;22(6):494–504.
- Anderson KE, Van Duijn E, Craufurd D, et al. Clinical management of neuropsychiatric symptoms of Huntington disease: expert-based consensus guidelines. J Huntingt Dis. 2018;7(4):355–366.
- Quinn L, Kegelmeyer D, Kloos A, et al. Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology. 2020;94(5):217–228.
- Harrison MB, Morrissey DL, Dalrymple WA, et al. Primary palliative care in Huntington's disease. Mov Disord Clin Pract. 2023;10(1):55–63.
- Stoker TB, Mason SL, Greenland JC, et al. Huntington's disease: diagnosis and management. Pract Neurol. 2022;22(1):32–41.
- Eyre M, Thomas T, Ferrarin E, et al. Treatments and outcomes among patients with Sydenham chorea: a meta-analysis. JAMA Netw Open. 2024;7(4):e246792.